Development of the treatment for autoimmune disorders using human tolerogenic dendritic cells induced by protein kinase C inhibitor.
| Project/Area Number |
26860752
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Collagenous pathology/Allergology
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
Matsumoto Takuya 愛媛大学, 医学部附属病院, 講師(病院教員) (70724780)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 免疫寛容樹状細胞 / Cキナーゼ阻害剤 / Ｃキナーゼ阻害剤 / 制御性Ｔ細胞 |
|---|
| Outline of Final Research Achievements |
Previously, we reported that we could induce tolerance dendritic cell (tDCs) which had strong immune tolerance ability with the stability in the condition of the inflammatory environment by using C kinase inhibitors (PKCI) in the maturity process of the dendritic cell of human. In addition, we made a comparison between PKCI-tDCs and tDCs derived other materials, PKCI-tDCs was shown to be superior effects than other tDCs. Also PKCI-tDCs could be derived from the peripheral blood of the patient with collagen diseases (Sjogren's syndrome and rheumatoid arthritis). From these results mentioned above, PKCI-tDCs might have useful possibility in clinical application.
|
Report
(4 results)
Research Products
(5 results)
